Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381595 | 0.90 | CTPS1 (1.00) | CTPS1 | |
| SCHEMBL21384756 | 0.88 | CTPS1 (0.67) | CTPS1 | |
| SCHEMBL30528838 | 0.88 | CTPS1 (0.67) | CTPS1 | |
| SCHEMBL30528795 | 0.88 | CTPS1 (0.76) | CTPS1CTPS2 | |
| SCHEMBL21384639 | 0.88 | CTPS1 (0.76) | CTPS1CTPS2 | |
| SCHEMBL24107100 | 0.85 | CTPS1 (0.68) | CTPS1CTPS2 | |
| SCHEMBL21384632 | 0.85 | CTPS1 (0.68) | CTPS1CTPS2 | |
| SCHEMBL30528893 | 0.85 | CTPS1 (0.68) | CTPS1CTPS2 | |
| SCHEMBL21381537 | 0.85 | CTPS1 (0.68) | CTPS1CTPS2 | |
| SCHEMBL30518342 | 0.85 | CTPS1 (0.68) | CTPS1CTPS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637770-A1 | CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER | Step Pharma S.A.S. (FR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4486347-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | Step Pharma S.A.S. (FR) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804752-A | Combination of CTPS1 and BCL2 inhibitors for the treatment of cancer | 斯泰普制药股份公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024133721-A1 | COMBINATIONS OF CTPS1 INHIBITOR WITH IAP INHIBITOR FOR USE IN THE TREATMENT OF CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023166076-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166080-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A WEE1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166077-A1 | COMBINATION OF A CTPS1 INHIBITOR AND A ATR INHIBITOR IN CANCER THERAPY | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166078-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| CN-111868051-A | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2020-10-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | CTPS1 1/4885CTPS2 2/4885 |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | CTPS1 1/4885CTPS2 2/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885CTPS2 2637/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885CTPS2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.